UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

Fosså, SD; Kaye, SB; Mead, GM; Cullen, M; de Wit, R; Bodrogi, I; ... Collette, L; + view all (1998) Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol , 16 (2) 716 - 724.

Full text not available from this repository.

Abstract

To determine the effect of r-metHu granulocyte colony-stimulating factor (G-CSF) on the proportion of patients with metastatic poor-prognosis malignant germ cell tumors who receive full dose-intensity combination chemotherapy.

Type:Article
Title:Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
Location:UNITED STATES
Language:English
Keywords:Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Cisplatin, Etoposide, Germinoma, Granulocyte Colony-Stimulating Factor, Humans, Male, Middle Aged, Prognosis, Recombinant Proteins
UCL classification:UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > MRC Clinical Trials Unit at UCL

Archive Staff Only: edit this record